The use of isolated limb infusion in limb threatening extremity sarcomas

International Journal of Hyperthermia

Volumn 29, Issue 1, 2013, Pages 1-7

  Vohra, Nasreen A ^a   Turaga, Kiran K ^b   Gonzalez, Ricardo J ^a,c   Conley, Anthony ^a,c   Reed, Damon ^a   Bui, Marilyn M ^a   Cheong, David ^a,c   Letson, Douglas G ^a,c   Zager, Jonathan S ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

ILI; Isolated limb infusion; Melphalan; Soft tissue sarcoma; Unresectable extremity sarcoma

Indexed keywords

DACTINOMYCIN; DEXAMETHASONE; MELPHALAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; ISOLATED LEG PERFUSION; MALE; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

EID: 84872309033     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2012.740548     Document Type: Article

References (33)

1. Brennan MF. Soft tissue sarcoma: Advances in understanding and management. Surgeon 2005;3:216-223
2. Rooser B, Gustafson P, Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma? Cancer 1990;65:1727-1729
3. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269-275
4. Stotter A. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;216:615-616
5. Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer 1991;67:2083-2086
6. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limbsparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315
7. Paredes T, Pereira M, Moreira H, Simo?es MR, Canavarro MC. Quality of life of sarcoma patients from diagnosis to treatments: Predictors and longitudinal trajectories. Eur J Oncol Nurs 2011;15:492-499
8. Ferrone ML, Raut CP. Modern surgical therapy: Limb salvage and the role of amputation for extremity soft-tissue sarcomas. Surg Oncol Clin N Am 2012;21:201-213
9. Davidge KM, Wunder J, Tomlinson G, Wong R, Lipa J, Davis AM. Function and health status outcomes following soft tissue reconstruction for limb preservation in extremity soft tissue sarcoma. Ann Surg Oncol 2010;17:1052-1062
10. Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011;29:4036-4044
11. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-Alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:1776-1784
12. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol 2008;15:2749-2756
13. Turaga KK, Beasley GM, Kane JM III, Delman KA, Grobmyer SR, Gonzalez RJ, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg 2011;146:870-875
14. Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol 2007;14:568-576
15. Wray CJ, Benjamin RS, Hunt KK, Cormier JN, Ross MI, Feig BW. Isolated limb perfusion for unresectable extremity sarcoma: Results of 2 single-institution phase 2 trials. Cancer 2011;117:3235-3241
16. Bonvalot S, Rimareix F, Causeret S, Le Pe'choux C, Boulet B, Terrier P, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoidtype fibromatosis with TNF 1mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol 2009;16:3350-3357
17. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15:3003-3013
18. Beasley GM, Ross MI, Tyler DS. Future directions in regional treatment strategies for melanoma and sarcoma. Int J Hyperthermia 2008;24:301-309
19. Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, et al. A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009;208:706-715; discussion: 715-707
20. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-247
21. Thompson JF, Kam PC. Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88:1-3
22. National Cancer Institute. Cancer Therapy Evaluation P: Common terminology criteria for adverse events. (CTCAE). v. 4.0. Bethesda, MD: National Institute of Health, 2009
23. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-910
24. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: Implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010;20:1456-1467
25. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, et al. Soft tissue sarcoma. J Natl Compr Cancer Network 2010;8:630-674
26. Dagan R, Indelicato DJ, McGee L, Morris CG, Kirwan JM, Knapik J, et al. The significance of a marginal excision after preoperative radiation therapy for soft tissue sarcoma of the extremity. Cancer 2012;118:3199-3207
27. Deneve JL, Zager JS. Isolated regional therapy for advanced extremity soft tissue sarcomas. Surg Oncol Clin N Am 2012;21:287-299
28. Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: Factors predictive of acute regional toxicity. Expert Opin Drug Metab Toxicol 2010;6:1039-1045
29. Moller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. IntJ Hyperthermia 2008;24:275-289
30. Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: A multi-institutional analysis. Ann Surg Oncol 2009;16:2570-2578
31. Schraffordt Koops H, Oldhoff J, Oosterhuis JW, Beekhuis H. Isolated regional perfusion in malignant melanoma of the extremities. World J Surg 1987;11:527-533
32. Bonvalot S, Laplanche A, Lejeune F, Stoeckle E, Le Pe'choux C, Vanel D, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-Alpha be better? Ann Oncol 2005;16:1061-1068
33. Riedel RF. Targeted agents for sarcoma: Is individualized therapy possible in such a diverse tumor type? Semin Oncol 2011;38S3:S30-42